Breast cancer treatment multiple options

Breast cancer, the most common malignant neoplasm in women around the world, has evolved in its treatment strategies, especially the development of target-to-treatment, which has brought more treatment options and better survival prospects for patients. The following is a brief overview of the targeted treatment of breast cancer: 1. Her2 positive breast cancer: Her2 is an important driver of breast cancer and a preset indicator. Anti-HER2 targeting treatments, such as Herceptin and Perjeta, have become important treatments for HeR2 positive breast cancer. In addition, anti-vegetative drugs such as Kadcyla (T-DM1) and Enhertu provide new treatment options for HeR2-positive patients. These drugs, combined with a specific HER2 receptor, cut off their signal circuits for tumour growth, thus inhibiting the growth of tumour cells. 2. Targeting treatment for HIV positive/HER2 negative breast cancer: For hormonal positive patients, CDK4/6 inhibitors such as Ibrance (palbocicclib), Kisqali (ribocclib) in Novara and cerzenio (abemacicclib) and hormonal therapy have become standard first-line treatments for transsexual patients. These drugs prevent the growth of cancer cells by inhibiting the activity of CDK4/6 protein. 3. Targeting treatment for triple-negative breast cancer: Due to the lack of representation of Her2 and hormone receptors, the response to Her2-targeting and hormone therapy is poor. However, immunotherapy and PARP inhibitors provide new strategies for this type of breast cancer treatment. For example, both PD-L1 inhibitors Tecentriq and PD-1 inhibitors Keytruda have been approved for treatment of transsexual triple-negative breast cancer, while PARP inhibitors, such as Lynparza and Talzenna, are targeted at patients carrying a mutation of the BRCA1/2 gene. 4. New trends in breast cancer treatment: With the in-depth study of molecular and tumour micro-environments for breast cancer, progress has been made in the development of target-to-treatment drugs. For example, new ADC drugs, such as T-DXd (DS-8201), have shown significant efficacy in providing new treatment options for low-expressed HeR2 breast cancer patients. 5. Individualization of breast cancer treatment: individualized treatment is possible as genetic and genetic research on breast cancer deepens. The BRCA genetic tests and the application of the PARP inhibitor provide a more precise treatment strategy for breast cancer patients carrying the BRCA mutation. In summary, the target of breast cancer is moving towards more precise and individualized treatment, providing patients with more treatment options and better survival prospects. The treatment of breast cancer will become more diverse and effective in the future as new drugs continue to be developed and clinically tested.